UBS Group
DMAAR

UBS Group’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

UBS Group’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12 Buy
+108
New +$11 ﹤0.01% 10314
2025
Q4 		– Sell
-150
Closed -$33 – 11478
2025
Q3 		$33 Buy
+150
New +$28 ﹤0.01% 10068

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

UBS Group's DMAAR Position: Q2 2026 in Review

UBS Group opened a new position in Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026: 108 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #10314 among its holdings. This is a return to the name: UBS Group previously reported a position in DMAAR as recently as Q3 2025.

UBS Group first reported a position in DMAAR in Q3 2025 and has held it in 2 quarters since. The position peaked at $33 in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • UBS Group held 108 shares of Drugs Made In America Acquisition Corp Rights worth $12 as of Q2 2026.
  • Drugs Made In America Acquisition Corp Rights was a new UBS Group position in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10314 holding.
  • UBS Group first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 2 quarters since.
  • UBS Group's Drugs Made In America Acquisition Corp Rights position peaked at $33 in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.